In Brief: SmithKline Beecham
SmithKline Beecham: Agrees to purchase Eastman Kodak's former Sterling Winthrop R&D complex in Upper Providence, Penn. for $120 mil. in cash, SB announces April 7. Sterling had estimated construction cost of the site to be $365 mil. ("The Pink Sheet" May 17, 1993, T&G-14). The 150-acre site, with nine buildings and almost 1 mil. square feet of laboratories, offices and support facilities, will be used by SB for pharmaceutical R&D. An initial 500 employees from SB's West Conshohocken, Penn. facility will be relocated to the new complex...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth